Table 2 Patients’ characteristics with non-metastatic gastric cancer
|  | BCc1 nanomedicine (n = 30) | Placebo (n = 30) |
|---|---|---|
Age, years | ||
 Mean (SD) | 65 ± 10.5 | 61 ± 11.4 |
Weight | ||
 Mean (SD) | 62 ± 14 | 59 ± 11 |
Gender (n) | ||
 Male–female | 20–10 | 14–19 |
Stage (n) | ||
 I | 3 | 1 |
 II | 3 | 8 |
 III | 19 | 13 |
Site of involvement (n) | ||
 Cardia | 10 | 9 |
 Antrum | 9 | 6 |
 Fundus | 0 | 3 |
 Greater curvature | 3 | 1 |
 Lesser curvature | 7 | 5 |
 Diffuse | 2 | 2 |
Intervention + chemotherapy (n) | 12 | 20 |
Intervention chemotherapy + radiotherapy (n) | 1 | 2 |